Source: Mac Slavo
Pfizer, the drugmaker of one of the COVID-19 vaccines said nearly 36,000 of the volunteers have already received the second of its two-dose of the vaccine. This vaccine is in the very late stages of trials now.
The phase three trials are a critical last step needed to get the vaccines cleared for distribution. Three other U.S.-backed candidates are in phase three: Pfizer expects to apply for an emergency use authorization with the Food and Drug Administration next month.
[This vaccine] contains genetic material called messenger RNA, or mRNA, which scientists hope provokes the immune system to fight the virus.
In September, Pfizer expanded the enrollment of its phase three trial to up to 44,000 volunteers from the initial target of up to 30,000. The company said the expansion would allow it to further increase diversity in the trial as well as include adolescents as young as 16 years old and people with preexisting conditions. –CNBC
Pfizer said their data monitoring board, which will assess whether the trial has been successful, has not conducted an interim efficacy analysis yet.
Pfizer has already begun the mass production of its COVID-19 vaccines even though they are still at the end of phase three trials. It’s too bad people are going to line up to get injected with this concoction. Once it is approved, expect the military and other private companies to begin rolling out this vaccine.